Federal health authorities recently approved an experimental drug, Donanemab, developed by Eli Lilly, for early-stage Alzheimer's patients. This marks the second FDA-approved medication that has shown to delay the progression of the disease by physically altering its course, rather than just addressing symptoms. In trials, Donanemab demonstrated a significant reduction in cognitive decline and functional impairment, with a 35% decrease in decline after 18 months. The drug targets amyloid protein deposits in the brain, a key indicator of Alzheimer's presence, and is administered through infusion every four weeks. While the drug is expected to be costly, at almost $700 per vial and a year's course estimated at $32,000, Medicare and Medicaid plan to cover it. Despite some potential side effects, including brain swelling or bleeding, the FDA deemed the benefits of Donanemab outweigh the risks, signaling a promising step towards evolving Alzheimer's treatment and providing hope for those affected by the disease.